Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Energy restriction, widely known as caloric restriction, is a dietary intervention that involves reducing total calorie intake without causing malnutrition. It is not a single molecular target or receptor but rather a systemic physiological state that triggers a complex network of metabolic and cellular adaptations. This state is characterized by the downregulation of growth-promoting pathways, such as the Mechanistic Target of Rapamycin (mTOR) and Insulin/IGF-1 signaling, and the upregulation of energy-sensing and survival pathways, including Adenosine Monophosphate-activated Protein Kinase (AMPK) and Sirtuins (National Institute on Aging, 2023). These molecular shifts promote cellular maintenance, enhance DNA repair, and induce autophagy, which collectively contribute to delayed biological aging and a reduced incidence of chronic diseases such as cancer, diabetes, and neurodegeneration (Madeo et al., Nature Reviews Drug Discovery, 2019). In the context of drug discovery, energy restriction serves as the gold-standard physiological model for longevity and metabolic health. Researchers focus on developing 'caloric restriction mimetics' (CRMs), which are pharmacological agents designed to induce the beneficial biochemical effects of energy restriction without requiring a reduction in food intake. Common examples include Metformin, which activates AMPK, and Rapamycin, which inhibits mTOR. While energy restriction itself is a lifestyle intervention, the pathways it activates are primary therapeutic targets for treating metabolic syndrome and age-related pathologies (Fontana et al., Science, 2010).
Energy restriction functions by modulating nutrient-sensing pathways, specifically through the activation of Adenosine Monophosphate-activated Protein Kinase (AMPK) and Sirtuins (e.g., SIRT1), and the simultaneous inhibition of the Mechanistic Target of Rapamycin (mTOR) and the Insulin/IGF-1 signaling axis (Fontana & Partridge, Cell, 2015).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Energy restriction (ER).